Quest Diagnostics (DGX) Expected to Release Quarterly Earnings on Thursday

Quest Diagnostics (NYSE:DGX) is expected to be releasing its Q2 2026 results before the market opens on Thursday, July 23rd. Analysts expect Quest Diagnostics to post earnings of $2.81 per share and revenue of $2.9727 billion for the quarter. Parties may visit the the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, July 23, 2026 at 8:30 AM ET.

Quest Diagnostics (NYSE:DGX) last announced its quarterly earnings data on Tuesday, April 21st. The medical research company reported $2.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.37 by $0.13. Quest Diagnostics had a net margin of 9.07% and a return on equity of 15.60%. The company had revenue of $2.90 billion for the quarter, compared to analysts’ expectations of $2.83 billion. During the same quarter in the previous year, the company posted $1.94 EPS. The business’s revenue was up 9.2% compared to the same quarter last year. On average, analysts expect Quest Diagnostics to post $11 EPS for the current fiscal year and $12 EPS for the next fiscal year.

Quest Diagnostics Stock Down 1.5%

DGX stock opened at $207.44 on Tuesday. The firm has a market cap of $22.96 billion, a PE ratio of 22.92, a P/E/G ratio of 2.51 and a beta of 0.58. Quest Diagnostics has a 12 month low of $165.30 and a 12 month high of $219.20. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.18 and a quick ratio of 1.08. The firm has a 50 day simple moving average of $200.87 and a 200 day simple moving average of $196.50.

Quest Diagnostics Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, July 22nd. Shareholders of record on Wednesday, July 8th will be issued a $0.86 dividend. The ex-dividend date of this dividend is Wednesday, July 8th. This represents a $3.44 annualized dividend and a dividend yield of 1.7%. Quest Diagnostics’s dividend payout ratio is currently 38.01%.

Insider Activity

In other Quest Diagnostics news, SVP Karthik Kuppusamy sold 8,147 shares of Quest Diagnostics stock in a transaction dated Thursday, June 4th. The stock was sold at an average price of $200.00, for a total transaction of $1,629,400.00. Following the transaction, the senior vice president owned 13,510 shares of the company’s stock, valued at $2,702,000. The trade was a 37.62% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO J. E. Davis sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $194.14, for a total transaction of $1,941,400.00. Following the sale, the chief executive officer owned 132,423 shares of the company’s stock, valued at approximately $25,708,601.22. This represents a 7.02% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 0.88% of the company’s stock.

Hedge Funds Weigh In On Quest Diagnostics

Several institutional investors and hedge funds have recently modified their holdings of the stock. Boston Partners boosted its stake in Quest Diagnostics by 32.8% during the 3rd quarter. Boston Partners now owns 4,036,881 shares of the medical research company’s stock valued at $767,978,000 after purchasing an additional 997,033 shares during the period. EdgePoint Investment Group Inc. increased its position in Quest Diagnostics by 95.5% in the 4th quarter. EdgePoint Investment Group Inc. now owns 1,661,072 shares of the medical research company’s stock worth $288,246,000 after buying an additional 811,320 shares during the period. Bank of America Corp DE increased its position in Quest Diagnostics by 36.3% in the 2nd quarter. Bank of America Corp DE now owns 1,599,602 shares of the medical research company’s stock worth $287,337,000 after buying an additional 426,399 shares during the period. Morgan Stanley lifted its holdings in shares of Quest Diagnostics by 17.8% during the fourth quarter. Morgan Stanley now owns 2,693,568 shares of the medical research company’s stock worth $467,415,000 after buying an additional 406,658 shares during the last quarter. Finally, Marshall Wace LLP boosted its position in shares of Quest Diagnostics by 171.7% in the third quarter. Marshall Wace LLP now owns 557,155 shares of the medical research company’s stock valued at $106,183,000 after acquiring an additional 352,072 shares during the period. 88.06% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently commented on DGX shares. Truist Financial increased their price objective on Quest Diagnostics from $220.00 to $225.00 and gave the company a “hold” rating in a research report on Wednesday, April 22nd. Evercore set a $225.00 target price on Quest Diagnostics in a research report on Tuesday, April 21st. Robert W. Baird upped their target price on Quest Diagnostics from $232.00 to $236.00 and gave the company a “neutral” rating in a report on Monday, July 13th. Barclays increased their price target on Quest Diagnostics from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Wednesday, April 22nd. Finally, Wall Street Zen cut Quest Diagnostics from a “buy” rating to a “hold” rating in a research note on Monday. Seven research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. According to MarketBeat, Quest Diagnostics has a consensus rating of “Moderate Buy” and an average price target of $217.17.

About Quest Diagnostics

Quest Diagnostics (NYSE: DGX) is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.